Uploaded February 2026 | Updated November 2026, 4 days ago
The FDA has cleared the first human trial of an age-rejuvenating gene therapy, ER-100, to test safety and vision outcomes using controlled epigenetic reprogramming.
The FDA has cleared the first human trial of an age-rejuvenating gene therapy, ER-100, to test safety and vision outcomes using controlled epigenetic reprogramming.










